A key part of Pharma Integrates’ agenda revolved around the efficacy of different types of treatment, how to get therapies to patients quickly and effectively, the impact of personalised medicine, technological advances in drug discovery and tackling rare diseases.
With investment in the digital health sector reaching a record $8.1bn (£6.2bn) in 2018 and with one third of all US healthcare investment now in digital health technology, it is becoming increasingly important that the life sciences sector keeps up to date with the latest technological advances.
A company’s staff is its greatest asset, but with every business struggling to recruit and retain key talent, and with the very real threat of a Brexit “brain drain”, how can the life sciences industry attract the best and brightest?
In an ever-changing pharmaceutical industry, both in terms of innovation and R&D, as well as from a business and funding perspective, the subject of strategic development and tactics to boost productivity was firmly on the agenda at November’s Pharma Integrates.
The issues surrounding patient engagement sparked lively debate at our inaugural Bio Integrates conference.
Established by Innovate UK, Catapult centres were set up from 2011 onwards following the publication of an influential report in 2010 as part of the Government’s long-term Industrial Strategy to promote research and development through business-led collaboration.
What will the next generation of ATMPs look like?
Hear insights from experts from @TheCandGC, @theRSAgroup, @OnkTherapeutics, @Theolytics, @CGTCatapult, @SymbiosisPharma, @HZDiscovery, @KinomicaLtd, @NanoSyrinx, @ImmtuneTx, @LillyPad
https://www.lifescienceintegrates.com/product/advanced-therapies-integrates-tickets-2021/
